From Shared Science to Regional Strength: Advancing mRNA R&D and Regional Manufacturing for Pandemic Preparedness
주최 기관 (Host Institution)
Medicines Patent Pool
날짜 (Date)
Tuesday, 16 September 2025
시간 (Time)
11:30 – 13:30 KST
장소 (Venue)
Marronnier [3rd Floor]
언어 (Language)
English
세션 시놉시스 (Session Synopsis)
This session will showcase how the WHO and MPP co-led mRNA Technology Transfer Programme is building a regional ecosystem for innovation, regional manufacturing, and capacity strengthening to advance pandemic preparedness. Thailand’s leading institutions — Chulalongkorn University, Chula VRC, and Mahidol University — are anchoring R&D consortia on HPV, malaria, dengue, and HFMD, with partners across Southeast Asia. Manufacturers Polyvac (Vietnam) and Incepta (Bangladesh), along with Afrigen (South Africa), are advancing mRNA platforms to enhance regional autonomy. Korea’s International Vaccine Institute supports training and regulatory alignment. The session will highlight licensing, progress, and policy levers enabling equitable, sustainable mRNA innovation.
주요 연사 (Main Speakers)
Martin Friede MPP
Petro Terblanche Afrigen
Jerome Kim IVI
Kiat Ruxungtham
R&D consoritia person
Incepta
Polyvac
세부 프로그램 (Detailed Program)
TBD
Program
Venue: Marronnier [3rd Floor]
From Shared Science to Regional Strength: Advancing mRNA R&D and Regional Manufacturing for Pandemic Preparedness
〈 Medicines Patent Pool 〉
항목 / Item
내용 / Content
세션 제목 / Session Title
From Shared Science to Regional Strength: Advancing mRNA R&D and Regional Manufacturing for Pandemic Preparedness
주최 기관 / Host Institution
Medicines Patent Pool
날짜 / Date
Tuesday, 16 September 2025
시간 / Time
11:30 - 13:30 KST
장소 / Venue
Marronnier [3rd Floor]
언어 / Language
English
세션 시놉시스 / Session Synopsis
This session will showcase how the WHO and MPP co-led mRNA Technology Transfer Programme is building a regional ecosystem for innovation, regional manufacturing, and capacity strengthening to advance pandemic preparedness. Thailand’s leading institutions — Chulalongkorn University, Chula VRC, and Mahidol University — are anchoring R&D consortia on HPV, malaria, dengue, and HFMD, with partners across Southeast Asia. Manufacturers Polyvac (Vietnam) and Incepta (Bangladesh), along with Afrigen (South Africa), are advancing mRNA platforms to enhance regional autonomy. Korea’s International Vaccine Institute supports training and regulatory alignment. The session will highlight licensing, progress, and policy levers enabling equitable, sustainable mRNA innovation.
